Rare diseases put a tremendous burden on our healthcare system. With over 80% of rare diseases thought to be genetic in origin, children with such diseases face tough hurdles and considerable expense on their diagnostic journey. Now, a comprehensive method for analyzing entire genomes, whole-genome sequencing (WGS) is quickly dropping sequencing costs making critical genetic tests more cost-effective, sparing patients unnecessary tests and procedures.
Join Brock Schroeder, Senior Director of Market Access Strategy & HEOR at Illumina; Danny Miller, CEO of MEPAN Foundation; and Austin Larson, Assistant Professor at the University of Colorado School of Medicine on Thursday September 24, 2020 at 2pm ET as they discuss the value of genome sequencing for patients, payers, and hospitals. Register here.